<DOC>
	<DOCNO>NCT00758446</DOCNO>
	<brief_summary>This phase II study patient seasonal allergic rhinitis ( SAR ) compare effect versus placebo two different oral dos BLX-028914 allergen challenge model . BLX-028914 , selective phosphodiesterase-4 ( PDE4 ) inhibitor promise safety profile , currently development treatment airway diseases Orexo AB , Sweden . The aim study compare effect , safety tolerability 14 day treatment BLX-0289014 patient SAR allergen challenge model versus placebo .</brief_summary>
	<brief_title>Efficacy Safety Study BLX-028914 Subjects With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>18 50 year age ( inclusive ) , male female Body Mass Index ( BMI ) 18 28 kg/m2 ( inclusive ) History polleninduced seasonal allergic rhinitis otherwise healthy Positive skin prick test timothy and/or birch allergen Sufficient reaction nasally administer allergen screen Signed informed consent obtain Expected symptom seasonal allergic rhinitis study period Asthma Nasal anatomical deviation , ongoing nasal symptom , ongoing upper respiratory tract infection Antiallergy immunotherapy previous two year Extensive use nasal spray Any medication except contraceptive , last five half life prior first treatment period except occasional OTC analgesic Ingestion grapefruit grapefruit juice herbal remedy ( e.g . St John'swort ) may effect enzyme CYP3A4 Smoking within 3 month first treatment period Clinically significant laboratory finding Pregnant breast feed woman woman childbearing potential use adequate birth control Known hypersensitivity constituent study medication placebo Participation investigational study last three month Subject anticipate able adhere study plan accord investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>